ChemAesthetic IGF1 LR3 1mg

IGF-1 LR3 (Long Arg3 IGF-1) is a recombinant analogue of insulin-like growth factor 1 (IGF-1) with an N-terminal methionine extension and substitution of glutamic acid with arginine at position 3. These modifications dramatically reduce binding affinity for IGF binding proteins (IGFBPs), extending its half-life from approximately 15 minutes (native IGF-1) to 20–30 hours and increasing the proportion of bioavailable, receptor-active IGF-1.

IGF-1 Biology and the GH Axis

IGF-1 is a 70-amino-acid polypeptide produced primarily by the liver in response to GH signalling via the JAK2-STAT5 pathway. It acts as the primary mediator of GH's anabolic effects — stimulating skeletal muscle hypertrophy, bone longitudinal growth, and cell proliferation across multiple tissue types. Circulating IGF-1 is almost entirely bound to one of six IGF binding proteins (IGFBP-1 through IGFBP-6), which regulate its bioavailability, tissue distribution, and receptor accessibility.

The high IGFBP affinity of native IGF-1 means that most circulating IGF-1 is biologically inactive, serving as a reservoir. The small fraction of free IGF-1 (approximately 1-2% of total) is what binds IGF-1 receptor (IGF-1R) to activate downstream signalling.

Structural Modifications of LR3

The LR3 modification addresses the IGFBP binding problem directly. The Arg3 substitution dramatically reduces IGFBP-3 and IGFBP-5 binding affinity (the primary circulating binding proteins), while the N-terminal extension further modifies the protein's IGFBP interaction surface. The result is a form of IGF-1 that circulates predominantly in free, receptor-accessible form with a half-life that makes single-dose in-vivo studies practical.

IGF-1R Signalling and Cellular Effects

IGF-1 LR3 binds and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally homologous to the insulin receptor. Downstream signalling cascades include:

• PI3K-Akt-mTOR pathway: Drives protein synthesis via mTORC1 activation, promoting muscle hypertrophy and cell growth. Akt also phosphorylates and inhibits FoxO transcription factors, reducing protein catabolism (atrogin-1/MAFbx and MuRF-1 ubiquitin ligase expression).
• Ras-MAPK-ERK pathway: Promotes cell proliferation and differentiation, particularly in satellite cells (muscle stem cells) and fibroblasts.
• Anti-apoptotic signalling: Akt phosphorylates Bad and activates NF-κB, reducing apoptotic susceptibility — relevant in neuroprotection and ischaemia research.

Muscle Research Applications

IGF-1 LR3 has been widely used in skeletal muscle research to study hypertrophy and atrophy mechanisms. In-vitro studies in C2C12 myotubes and primary human myoblasts demonstrate dose-dependent increases in protein synthesis rates, myotube diameter, and satellite cell proliferation. In-vivo rodent studies show significant lean mass gains with prolonged IGF-1 LR3 administration. These models are used to study muscular dystrophy, sarcopenia, and cancer cachexia mechanisms.

Satellite Cell and Muscle Regeneration

Muscle satellite cells (muscle stem cells) express high levels of IGF-1R and are critically regulated by IGF-1 signalling. IGF-1 LR3 promotes satellite cell activation, proliferation, and differentiation into myotubes after muscle damage — making it a valuable tool in muscle regeneration research. The extended half-life versus native IGF-1 allows sustained satellite cell stimulation that is difficult to achieve with rapidly degraded native peptide.

Distinction from Des(1-3)IGF-1

Des(1-3)IGF-1 is another IGFBP-reduced IGF-1 variant (N-terminal truncation of first 3 residues). Both Des-IGF-1 and LR3 reduce IGFBP binding and increase bioavailability. LR3 retains the full 70-residue sequence (with the Arg3 substitution and Met extension) while Des(1-3) removes the binding site entirely. Their research profiles differ in binding to insulin receptor and cross-reactivity with IGFBP subtypes — researchers select between them based on specific assay requirements.

Hypoglycaemia Considerations in Research

IGF-1 LR3 binds the insulin receptor with approximately 1-5% of insulin's affinity, but at high concentrations can produce hypoglycaemic effects in animal studies. This insulin-like activity must be accounted for in research protocols, particularly in metabolic disease models.